A Phase 2 Open Label Study of REC-4881 in Participants with Unresectable Locally Advanced or Metastatic Cancer with AXIN1 or APC Mutation

Brief description of study

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.


Clinical Study Identifier: s23-01082
ClinicalTrials.gov Identifier: NCT06005974
Principal Investigator: Nina Beri.
Other Investigators: Nila Theresa De La Rosa, Joshua K Sabari, Samantha VanMaanen, Douglas K Marks, Salman Rafi Punekar, Elaine Shum, Jessica Wang, Kristen Spencer, Scot Niglio, Keriann M Scavone, Kirby Rodriguez, Kathleen M Madden, Nancy Chan, Eneil De La Pena, Janice Mehnert, David R. Wise.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.